enVVeno Medical (NVNO)

Executive Summary

enVVeno Medical Corporation is a commercial-stage medical device company addressing chronic venous insufficiency (CVI), a debilitating condition affecting millions globally. The company’s lead product, the VenoValve, is a first-in-class, non-implant-based solution designed to restore venous function through a minimally invasive procedure, offering a durable alternative to current surgical options. With a focus on a large underserved market and strong clinical data, enVVeno is positioned to capture significant share in the venous disease treatment space. The company is publicly traded (NASDAQ: NVNO) and continues to advance its regulatory and commercialization efforts. enVVeno’s VenoValve has demonstrated compelling safety and efficacy in pivotal trials, and the company is pursuing FDA premarket approval (PMA). If approved, it would become the first non-surgical treatment for deep venous reflux, addressing a critical unmet need. The company is also building commercial infrastructure to support launch. Given the binary nature of regulatory decisions and the potential for transformative market adoption, enVVeno represents a high-risk, high-reward opportunity in the medical device sector.

Upcoming Catalysts (preview)

• Q3 2026FDA PMA decision on VenoValve60% success
• Q4 2026Commercial launch and initial revenue50% success
• Q3 2026Publication of pivotal trial data in peer-reviewed journal80% success